Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: cellectar.com
NorthStar to provide non-carrier added actinium-225 (n.c.a Ac-225) to Cellectar for use in its expanded portfolio of clinical programs This includes CLR 121225 an actinium-labeled phospholipid ether (PLE), expected to enter a Phase 1 study in pancreatic cancer in 2025 NorthStar Medical Radioisotopes, LLC today announced the signing of a strategic Master Supply Agreement with Cellectar Biosciences, Inc. (NASDAQ:CLRB) under which Cellectar will acquire and integrate NorthStar's n.c.a. Ac-225 into Cellectar's proprietary Phospholipid Ethers (PLE) delivery platform to expand the platform's capability to produce a diverse range of radiotherapeutic molecules. NorthStar is a global innova
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise up to an additional $73.3 million Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2024, and provided a corporate update. "We achieved important clinical, operational
NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs FLORHAM PARK, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the signing of a strategic supply agreement with NorthStar Medical Radioisotopes, LLC, for the procurement of NorthStar's non-carrier added (n.c.a.) Ac-225. The Company's CLR 121225 development program combines its proprietary Phospholipid Ether (PLE) delivery platform and actinium 225 for the treatment of solid tumors. Existin
INDIANAPOLIS and FLORHAM PARK, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, and Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, have signed a commercial supply agreement for the manufacture of Cellectar's first-in-class cancer therapy, iopofosine I 131. "We continue strengthening our supply network, ensuring patients with advanced cancers in need of novel therapeutic options gain access to what we believe is a best-in-class treatment for Waldenstrom's macroglobulinemia (WM). Th
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Monday, November 18, 2024Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:80659Webcast:Click HERE A replay of the call will be available on the Events section of the company's investor relations website. About
Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study Highlights Company's Leadership and Progress in Developing Iopofosine I 131 as Treatment for Waldenstrom's Macroglobulinemia FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that new data from the company's open-label Phase 2 CLOVER-WaM study of iopofosine I 131 as a potential treatment for Waldenstrom's macroglobulinemia (WM) will be highlighted i
FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company, announced today it received a letter dated October 31, 2024, from Nasdaq, Inc. informing the Company that it had regained compliance with Nasdaq Listing Rule 5250(c)(1). The Company filed the following on October 29, 2024, with the Securities and Exchange Commission: (i) restated audited consolidated financial statements for the fiscal years ended December 31, 2023 and 2022 and restated quarterly financial statements for the periods ended March 31, 2023; June 30, 2023; September 30, 2023; March 31, 2022, June 30, 2022, and September 30, 2022 on F
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the Company had received an expected delinquency notification letter (the "Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") on August 20, 2024. The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quart
FLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2024, and provided a corporate update. "With our recent positive data announcement from the CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom's macroglobulinemia, we remain focused on filing our WM NDA in the fourth quarter of this year," said James Caruso, president and CEO of Cellectar. "We anticipate an accelerated six-month NDA review period and continue to prepar
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows: Conference Call & Webcast Details:Date: Tuesday, August 13, 2024Time: 8:30 am Eastern TimeToll Free:
U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday. The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&P 500 also rose, gaining, 0.14% to 5,572.07. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline Coca-Cola Company (NYSE:KO) reported better-than-expected second-quarter results and raised its guidance. The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.09% to 40,452.70 while the NASDAQ rose 0.62% to 18,119.84. The S&P 500 also rose, gaining, 0.32% to 5,582.32. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 1% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline GE Aerospace (NYSE:GE) reported better-than-expected second-quarter earnings and raised its FY24 outlook. GE Aerospace reported second-quarter 2024 adjusted revenue growth of 4% year-over-year to
Cellectar Biosciences Inc. (NASDAQ:CLRB) stock is trading lower Tuesday after the company shared results from its CLOVER WaM pivotal study. The study evaluated iopofosine I 131, a targeted radiotherapeutic candidate, for relapsed/refractory Waldenstrom’s macroglobulinemia (WM) — a type of cancer that begins in the white blood cells. As of May 31, the CLOVER WaM study’s results had an overall response rate (ORR) of 80% and a major response rate (MRR) of 56.4%. Results exceeded the agreed-upon primary endpoint of a 20% MRR. The median number of prior lines of therapy was four, with approximately 27% of patients refractory to all available therapies and 40% of patients dual-class refra
56.4% major response rate exceeded 20% primary endpoint · 98.2% disease control rate achieved in heavily pretreated patients · Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (BTKi and rituximab)
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warrants issued under its September 2023 private placement have been exercised for Series E preferred stock, convertible into the company's common stock, by the participants of the previous financing, led by Rosalind Advisors, in exchange for a reduced, as-converted common stock price of $2.52 and the purchase of new warrants. The exercised Tranche B warrants and newly purchased warrants will generate gross proceeds of approximately $19.4 million. The new warr
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)
8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
NT 10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)
8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)
10-Q/A - Cellectar Biosciences, Inc. (0001279704) (Filer)
10-K/A - Cellectar Biosciences, Inc. (0001279704) (Filer)
8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
NT 10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)
William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. "
ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio
FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior vice president hematology at TG Therapeutics, he oversaw the sales, marketing and analytics teams for the hematology franchise. Prior to TG Therapeutics, Mr. Lea served as vice president, hematology
Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances David Lasecki Appointed Executive Director, Strategic Alliances FLORHAM PARK, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced the appointment of Matthew Hagan as vice president, marketing and strategic alliances and David Lasecki as executive director, strategic alliances. "Matt and David each bring a wealth of experience and strong track records of success in the launching and marketing of oncology therapeutic
SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin
FLORHAM PARK, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced Laurence Reilly, M.D., LL.M as its interim chief medical officer. Dr. Reilly will oversee the company's clinical development programs and report to Chief Executive Officer James Caruso. He succeeds John Friend, MD, who is stepping down for personal reasons but will stay on through mid-November to finalize the ongoing transition. "We are delighted to welcome Laurence to our executive team and look forward to his leadership of our clinical develo
BOSTON--(BUSINESS WIRE)--AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer effective February 1, 2021. A seasoned financial and operational life sciences executive, Mr. Swirsky will be responsible for building out the Company’s financial, accounting, and facility functions to support AavantiBio’s growth and clinical development of its diversified pipeline of gene therapies. Mr. Swirsky, brings to AavantiBio more than 25 years of strategic, financial, and operational experience in the biopharmaceutical and healthcare sectors, inclu
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise up to an additional $73.3 million Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2024, and provided a corporate update. "We achieved important clinical, operational
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Monday, November 18, 2024Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:80659Webcast:Click HERE A replay of the call will be available on the Events section of the company's investor relations website. About
FLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2024, and provided a corporate update. "With our recent positive data announcement from the CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom's macroglobulinemia, we remain focused on filing our WM NDA in the fourth quarter of this year," said James Caruso, president and CEO of Cellectar. "We anticipate an accelerated six-month NDA review period and continue to prepar
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows: Conference Call & Webcast Details:Date: Tuesday, August 13, 2024Time: 8:30 am Eastern TimeToll Free:
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows: Conference Call & Webcast Details:Date:Tuesday, August 13, 2024Time:8:30 am Eastern TimeToll Free:1-800-717-1738Webcast:Click HERE A replay of
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (BTKi and rituximab) FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced positive results from its CLOVER WaM pivotal study evaluating iopofosine I 131, a potential first-in-class, targeted radi
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 2024, at 8:00 a.m., EDT, to provide a comprehensive overview of recent data from its pivotal trial of iopofosine I 131 in Waldenstrom's macroglobulinemia, the current treatment landscape, unmet needs for patients with this disease, and opportunities to improve patient outcomes. The event will feature both company leadership and key investigators, who will discuss the CLOVER WaM study (NCT02952508) and
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and provided a corporate update. "We plan to announce data from our CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom's macroglobulinemia in June and are on track to submit our NDA in the second half of 2024. We remain pleased with patient enrollment in the p
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended March 31, 2024, on Tuesday, May 14, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows: Conference Call & Webcast Details:Date: Tuesday, May 14Time: 8:30 am Eastern TimeToll Free: 1-800-717-1738Webcast: Click HERECall me™ Click HERE
FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update. "2023 was a year of significant progress for Cellectar, culminating in the January announcement of the positive data from our pivotal study of iopofosine I 131 in Waldenstrom's macroglobulinemia," said James Caruso, president, and CEO of Cellectar. "We continue to focus on the preparation of our NDA, which we plan to submit in the second half